Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

Helena Pomares, Iago Arribas, Teresa Quiñones, Jasson Villarreal Hernandez, Julia Ribes Amoros, Clara Maluquer Artigal, Shiomara Quiñones, Maria Isabel Sotelo, María Alicia Senin, Mercedes Galiano, Enric Gamundi, Lurdes Zamora, Neus Ruiz Xiville, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 4225.

https://doi.org/10.1182/blood-2023-178351

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Blood (2023) 142 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2023-173092

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Blood (2023) 142 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2023-179234

Published: 2023

Journal Articles

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Jasson Villarreal Hernandez, Helena Pomares, Antonella Sturla, Esther Alonso, Clara Maluquer Artigal, Rebecca Andersson, María Alicia Senin, Maria Teresa Encuentra, Mercedes Galiano, Lurdes Zamora, Marta Cabezón, Neus Ruiz Xiville, Maria Carolina Florian, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2023-187430

Published: 2023

Journal Articles

Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

Blood (2023) 142 (Supplement 1): 6477.

https://doi.org/10.1182/blood-2023-180680

Published: 2023

Journal Articles

Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

Iago Arribas, Helena Pomares, Teresa Quiñones, Jasson Villarreal Hernandez, Julia Ribes-Amoros, Clara Maluquer Artigal, Shiomara Quiñones, Maria Isabel Sotelo, María Alicia Senin, Mercedes Galiano, Enric Gamundí, Lurdes Zamora, Neus Ruiz Xiville, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5930.

https://doi.org/10.1182/blood-2023-189187

Published: 2023

Journal Articles

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Blood (2023) 142 (Supplement 1): 6425.

https://doi.org/10.1182/blood-2023-184980

Published: 2023

Journal Articles

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Salvador Carrillo-Tornel, Tzu Hua Chen-Liang, Ana Yeguas Bermejo, Helena Pomares, Alessandro Liquori, Teresa González, Teresa Bernal del Castillo, Marta Santiago, Félix López Cadenas, Bernardo López Andrade, Raul Teruel Montoya, Esperanza Such, Francisca Maria Hernandez, Blanca Xicoy, Montserrat Arnan Sangerman, Francesc Solé, Jose Cervera, Maria Diez-Campelo, Andres Jerez

Blood (2022) 140 (Supplement 1): 4074–4075.

https://doi.org/10.1182/blood-2022-168759

Published: 2022

Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 2063–2065.

https://doi.org/10.1182/blood-2022-158612

Published: 2022

Journal Articles

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

Helena Pomares, Villarreal Hernandez Jasson, Susana Vives, Marta Cervera, Rosa Coll, Lurdes Zamora, Clara Maluquer, Gladys Ibarra, Julia Ribes Amoros, Georgina Gener-Ricós, Mercedes Galiano, Anna Sureda, Montserrat Arnan Sangerman

Blood (2022) 140 (Supplement 1): 9021–9022.

https://doi.org/10.1182/blood-2022-168819

Published: 2022

Journal Articles

Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Jasson Villarreal Hernandez, Maria Condom, Helena Pomares, Susana Vives, Rosa Coll, Marta Cervera, Clara Maluquer, Gladys Ibarra Fernandez, Albert Torrents, Mercedes Galiano, Anna Sureda, Montserrat Arnan Sangerman

Blood (2021) 138 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2021-153100

Published: 2021

Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 698.

https://doi.org/10.1182/blood-2021-144905

Published: 2021

Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2021-144912

Published: 2021

Journal Articles

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Blood (2021) 138 (Supplement 1): 2610.

https://doi.org/10.1182/blood-2021-152678

Published: 2021

Journal Articles

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

María Diez-Campelo, Luis E. Benlloch, Emma Sasse, David Wormser, Leyla Hernandez Donoso, Silvia Colicino, Teresa Bernal, Antonieta Molero Yordi, Mar Tormo, Montserrat Arnan Sangerman, Guillermo Sanz, Marina Díaz-Beyá, María Teresa Cedena Romero, Andres Jerez, Brayan Merchán, David Valcárcel

Blood (2021) 138 (Supplement 1): 2605.

https://doi.org/10.1182/blood-2021-146019

Published: 2021

Journal Articles

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose Pérez-Simón, Rosa Coll, Montserrat Arnan Sangerman, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Sonia Gutierrez, Carlos Buesa, Francesc Bosch, Pau Montesinos

Blood (2021) 138 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2021-152183

Published: 2021

Journal Articles

Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis-Associated Speck-like Protein (ASC) and Reverted By IL1β Inhibitors

Blood (2021) 138 (Supplement 1): 3670.

https://doi.org/10.1182/blood-2021-153686

Published: 2021

Journal Articles

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Pilar Martínez, MD, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, MD, Javier Cornago Navascués, MD, Gabriela Rodriguez-Macías, MD, Isabel Cano, MD, Montserrat Arnan Sangerman, María-Belén Vidriales, MDPhD, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, MD, Angela Figuera Alvarez, MD PhD, Laida Cuevas Palomares, Marta Sobas, MDPhD, Alejandro Contento-Gonzalo, MD, Rebeca Cuello, MD, María Elena Amutio Diez, MD, Maria Dunia De Miguel, MD, Begoña Navas, MD, Juan Miguel Bergua Burgues, MD, Teresa Bernal del Castillo, MD PhD, María Carmen Mateos Rodríguez, MD, Erik de Cabo López, MD, Ana Carolina Franco Villegas, MD, Raimundo García-Boyero, MD, Cristian Escolano Escobar, MD, Cristina Seri, MD, Carlos Cervero, MD, Alicia Roldán Pérez, Maria Lourdes Hermosin, MD, Marta Cervera, MD, María Teresa Olave, MD, Paola Sandra Villafuerte Gutierrez, MD, Almudena De Laiglesia, MD, Josefina Serrano, MD, María Josefa Najera Irazu, MD, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, MD, Joaquin Martinez-Lopez, MD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138471

Published: 2020

Journal Articles

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Maite Antonio, MD PhD, Montserrat Arnan Sangerman, MD PhD, Eva Domingo-Domenech, MD, Eva González-Barca, MD PhD, Casimiro Javierre, MD PhD, Laura Hurtos, Judit Sola, Anna Sureda, MD PhD, Josep Maria Borras, MD PhD

Blood (2019) 134 (Supplement_1): 3424.

https://doi.org/10.1182/blood-2019-129908

Published: 2019

NARROW

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis-Associated Speck-like Protein (ASC) and Reverted By IL1β Inhibitors

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only